Tubeless anesthesia for VATS plus microwave ablation in patients with multiple high-risk ground-glass nodules

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, prospective randomized trial compares tubeless anesthesia to conventional endotracheal anesthesia during VATS combined with microwave ablation for multiple high-risk pulmonary ground-glass nodules. The primary outcome uses the PSA-LUNG patient-reported measure to assess postoperative symptoms and safety, along with technical success, perioperative complications, and lung function changes. 80 adults with suitable nodules are randomized 1:1 to receive either tubeless or conventional anesthesia. The study also explores tumor marker dynamics to inform perioperative anesthesia strategies. Conducted by The First Affiliated Hospital of Guangzhou Medical University, it aims to determine if tubeless anesthesia offers better patient recovery without compromising safety.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. aged ≥ 18 years
2. Chest CT revealed ≥2 multiple high-risk pulmonary ground-glass nodules (GGNs) that persisted for over 3 months. Following a multidisciplinary team (MDT) evaluation, these nodules were highly suspicious for malignancy. The nodules were required to meet the following criteria: Imaging criteria: Maximum diameter ≤2 cm and a consolidation-to-tumor ratio (CTR) ≤0.5 on chest CT. Surgical nodule criteria: Deemed amenable to wedge resection via intrathoracic surgical evaluation, with an anticipated surgical margin of ≥2 cm or ≥ the maximum diameter of the nodule. Ablation nodule criteria: Deemed unsuitable for wedge resection via intrathoracic surgical evaluation, primarily due to a location within the inner two-thirds of the lung parenchyma.
3. ECOG performance status: 0-1; preoperative systemic organ function was adequate for VATS and ablation.
4. ASA physical status: Class I-III
5. Preoperative PET-CT or other necessary imaging tests to exclude mediastinal and distant metastasis.
6. Expected survival ≥ 6 months; able to complete the study and follow-up as required.
7. Participants provided written informed consent and agreed to adhere to study visits, treatments, laboratory tests and related procedures.

Exclusion Criteria:

1. Prior pulmonary surgery, radiotherapy or other ablation within 3 months.
2. Contraindications to surgery, ablation or anesthesia; intolerance to tubeless anesthesia.
3. Planned concurrent treatments interfering with study results (e.g., systemic chemotherapy, targeted therapy).
4. Primary extrapulmonary malignancies or other active malignant diseases.
5. Failure to follow study rules or complete follow-up; refusal to provide informed consent or withdrawal of consent during the study.
6. Considered unsuitable for the study by investigators.
7. Enrollment in other concurrent clinical trials.

Where it's running

• The First Affiliated Hospital of Guangzhou Medical University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Xingyang Xue, PhD
• Email: xxy1023970@126.com
• Phone: +86-15876522723

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden

  This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.

  Recruiting Tongji Hospital · Hubei, Wuhan · NCT07912190

• Urine VOC Test to Detect Lung Cancer in Never Smokers

  A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07871656

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment

  This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07816263

• ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients

  This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.

  Recruiting at 2 sites Tam Anh Research Institute · Hanoi, Hanoi and 1 other locations · NCT07808164

• Olive oil before lung cancer surgery to see if it lowers chylothorax

  This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.

  Recruiting Fudan University · Shanghai, Xuhui · NCT07807696

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.